Vol.

No.

May 07, 2021May 07, 2021

Free

DOWNLOAD THE PDF

Menthol ban has been a no-brainer for decades—will it finally happen?

Cover Story

Free Guest Editorial

Menthol ban has been a no-brainer for decades—will it finally happen?

By Phoenix A. Matthews and Robert A. Winn

Mainstream tobacco control advocates are celebrating the recent announcement that the Food and Drug Administration is poised to restrict the manufacture and sale of mentholated cigarettes and cigars.

Free Guest Editorial

The unKOOL, unfiltered history of menthol cigarettes

By Alan Blum

Free

CTCA leaves Tulsa and Philadelphia; Tulsa move comes amid Blue Cross cost-cutting moves

By Paul Goldberg

Conversation with The Cancer Letter Free

Hinrichs reflects on his move from NCI to Rutgers Cancer Immunology and Metabolism Center of Excellence

By Paul Goldberg

Cancer History Project Free

A document in perspective: Otis Brawley on Frank J. Rauscher’s 1975 Cancer Program update

By Otis W. Brawley and Paul Goldberg

Free In the Archives

Answering big questions: Beatrice Mintz, Donald Pinkel, Baruch Blumberg, Irwin Rose

In Brief

Chanita Hughes-Halbert named associate director for cancer equity at USC Norris

MD Anderson, Syntropy enter into a system technology agreement

ASCO-ACCC piloting test tools to diversify cancer clinical trials

Naiyer Rizvi named CMO of Synthekine

Pearl McElfish named associate director of community outreach and engagement at UAMS Winthrop P. Rockefeller Cancer Institute

Pitt and IU researchers study cognitive dysfunction after chemotherapy

AICR awards $1.15 million for cancer prevention and survivorship

$12 million DoD grant establishes Convergent Science Virtual Cancer Center

Cancer research groups push emergency funding to restart clinical trials in infrastructure package

Clinical Roundup

Researchers find increased risk of mortality for Arizona’s Hispanic and Native American kidney cancer patients

NCI-MATCH has 12 open arms awaiting patients with advanced or rare cancers

NCCN releases new patient guidelines on anemia and neutropenia

UNC researchers examine approaches to deliver radiation to tumors while sparing healthy tissue

City of Hope opens phase II clinical trial to test if intake of mushroom-powder tablets could slow the progression of prostate cancer

Drugs & Targets

Keytruda receives FDA Accelerated Approval for HER2-positive gastric cancer

Tibsovo sNDA receives FDA acceptance and Priority Review for IDH1-mutated cholangiocarcinoma

Opdivo sBLA receives FDA acceptance and Priority Review for adjuvant treatment for patients with muscle-invasive urothelial carcinoma

Xtandi approved by European Commission for men with metastatic hormone-sensitive prostate cancer

Janssen submits Marketing Authorization Application to EMA seeking approval of cilta-cel for relapsed and/or refractory multiple myeloma

NCI Trials

NCI Trials for May 2021

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 05 - February 06, 2026